Market Pulse

Latest company updates, ordered by publication date.

eToro Group Ltd.

eToro's Growth Slows Amid Crypto Downturn, Share Buyback Signals Confidence

Event summary

  • eToro reported full-year 2025 net contribution of $868 million, a 10% year-over-year increase.
  • Fourth-quarter 2025 net contribution decreased by 10% year-over-year to $227 million.
  • Assets Under Administration (AUA) grew 11% year-over-year to $18.5 billion.
  • eToro’s board approved a $100 million increase to the share repurchase program, totaling $150 million.

The big picture

eToro's results reflect a mixed picture: while the company achieved record full-year contribution, the Q4 slowdown and declining crypto activity signal challenges in a shifting market. The share repurchase program suggests management believes the current valuation doesn't reflect the company’s potential, but also highlights a lack of immediate M&A targets. eToro's strategy of positioning itself as a bridge between traditional finance and the emerging on-chain world will be critical for long-term success.

What we're watching

Crypto Adoption
The decline in crypto trading volume suggests a potential shift in user behavior and may necessitate a diversification of revenue streams beyond crypto assets.
App Store Launch
The success of eToro’s planned App Store will hinge on attracting developers and users, and its ability to foster a vibrant ecosystem.
Regulatory Scrutiny
Increased regulatory focus on crypto and leveraged trading could impact eToro’s ability to expand its product offerings and access new markets.
Brunswick Exploration Inc.

Brunswick Exploration Expands Lithium Discovery, Targets Saudi Expansion

Event summary

  • Brunswick Exploration has restarted Phase 2 drilling at the Anatacau Main Project in Quebec, aiming to expand the Anais lithium discovery.
  • The Anais discovery previously yielded a significant intercept of 120 meters at 1.31% Li₂O in November 2025.
  • The current drilling program involves 2,500 meters across 12 inclined holes, with initial focus on expanding the Anais showing.
  • The Anais pegmatite has been extended to 250 meters in strike length and 115 meters vertical depth.
  • Brunswick Exploration anticipates releasing results from the drilling campaign in early Q2 2026, followed by prospecting in Saudi Arabia and exploration at the Mirage project.

The big picture

Brunswick Exploration's Anatacau Main Project sits within a strategically important lithium-rich corridor in Quebec, benefiting from proximity to Rio Tinto’s Galaxy Project. The company's aggressive exploration strategy, coupled with its expanding portfolio including projects in Greenland and Saudi Arabia, positions it to capitalize on the surging global demand for lithium, a critical component in electric vehicle batteries and energy storage systems. However, the company's valuation will be heavily influenced by the results of ongoing drilling programs and the successful development of its international assets.

What we're watching

Geological Risk
The success of the Phase 2 drilling hinges on the continued expansion of the Anais pegmatite and the identification of additional mineralized dykes along the deformation corridor, which is not guaranteed.
Saudi Expansion
Brunswick's foray into Saudi Arabia represents a significant geographic diversification, but its success will depend on navigating a new regulatory and operational environment.
Resource Estimate
The Mirage project's existing Inferred Mineral Resource Estimate of 52.2Mt grading 1.08% Li₂O will be tested by further exploration, and any upward revision could significantly impact the company's valuation.
Can-Fite BioPharma Ltd.

Can-Fite Data Suggests Obesity Treatment Potential for Liver Drug

Event summary

  • Can-Fite published a peer-reviewed study in the International Journal of Obesity demonstrating anti-obesity effects of namodenoson.
  • The study, based on in vitro and murine models, showed namodenoson inhibited adipocyte proliferation and reduced weight gain.
  • Findings align with previous Phase IIa data suggesting namodenoson’s impact on liver fat and body weight in MASH patients.
  • The global obesity treatment market is projected to reach $60.5 billion by 2030, with a 22% CAGR.

The big picture

Can-Fite’s data represents a potential strategic pivot for namodenoson, expanding its therapeutic scope beyond liver diseases into the massive obesity market. This repurposing strategy could accelerate revenue generation, but also introduces complexities in clinical development and regulatory approval. The company's existing pipeline and patent portfolio provide a foundation, but success hinges on demonstrating efficacy and safety in a new patient population.

What we're watching

Clinical Trials
The success of the ongoing Phase IIb MASH study will be critical in validating namodenoson’s broader therapeutic potential and influencing its obesity development pathway.
Regulatory Pathway
How regulatory agencies will view the repurposing of namodenoson for obesity, given its existing development for MASH and HCC, will shape the speed and cost of future trials.
Market Adoption
Whether Can-Fite can effectively position namodenoson within the competitive obesity treatment landscape, given the presence of established therapies and emerging novel approaches, will determine its commercial viability.
Waystar Holding Corp.

Waystar's AI Push Accelerates, Margin Expansion a Key Focus

Event summary

  • Waystar reported Q4 revenue of $304M, up 24% year-over-year, and FY revenue of $1,099M, up 17% year-over-year.
  • The company achieved a Q4 adjusted EBITDA margin of 43% and a FY adjusted EBITDA margin of 42%.
  • Waystar integrated the Iodine acquisition ahead of schedule, citing it as a driver of growth.
  • The company is guiding for FY 2026 revenue between $1.274 billion and $1.294 billion and adjusted EBITDA between $530 million and $540 million.

The big picture

Waystar's strong growth and margin expansion underscore the increasing demand for automated revenue cycle management solutions within the healthcare sector. The acquisition of Iodine signals a strategic bet on AI-driven capabilities, positioning Waystar to capitalize on the broader trend of digital transformation in healthcare. However, the company's valuation will be sensitive to its ability to execute on its AI roadmap and maintain its competitive advantage in a rapidly evolving market.

What we're watching

AI Adoption
The success of Waystar's AI-powered platform will hinge on provider adoption rates and the ability to demonstrate tangible ROI beyond current claims.
Margin Sustainability
Whether Waystar can maintain its high adjusted EBITDA margins as it scales and continues to invest in AI development and integration remains a key risk.
Client Retention
The net revenue retention rate, currently at 112%, will need to remain robust to validate the stickiness of Waystar's solutions and offset potential churn.
Nektar Therapeutics

Nektar Collaborates with UCSF, Leveraging TNFR2 Agonism for MS Research

Event summary

  • Nektar Therapeutics has initiated a research collaboration with UCSF and Dr. Stephen Hauser to investigate NKTR-0165, a TNFR2 agonist antibody, for potential treatment of multiple sclerosis (MS).
  • The collaboration will focus on exploring neuroprotection and cell repair mechanisms in MS models, utilizing patient-derived B cells.
  • UCSF will fund and conduct the research, while Nektar will supply NKTR-0165 and retain all rights to the program.
  • Dr. Hauser, a renowned neuroimmunologist and recipient of the 2025 Breakthrough Prize in Life Sciences, will lead the UCSF research team.
  • NKTR-0165 is currently in IND-enabling studies and is being developed for autoimmune and CNS disorders, including MS, vitiligo, and ulcerative colitis.

The big picture

Nektar's collaboration with UCSF represents a strategic move to leverage the expertise of a leading neuroimmunologist and academic institution in the development of novel MS therapies. The focus on TNFR2 agonism addresses a critical unmet need in MS treatment, targeting inflammation and neurodegeneration. This partnership underscores the increasing trend of biopharma companies collaborating with academic institutions to accelerate drug discovery and validation in complex neurological disorders.

What we're watching

Clinical Efficacy
The success of this collaboration hinges on demonstrating meaningful neuroprotective effects of NKTR-0165 in preclinical models, which will be crucial for advancing the program to clinical trials.
Regulatory Pathway
Given the complexity of MS and the existing treatment landscape, Nektar will need to carefully navigate regulatory pathways and demonstrate a clear clinical advantage for NKTR-0165 to achieve approval.
Pipeline Synergy
The learnings from NKTR-0165 development will inform the advancement of Nektar’s TNFR2 bispecific programs, particularly NKTR-0166, and the overall success of this strategy will depend on efficient translation of these insights.
Defense Metals Corp.

Defense Metals Advances Wicheeda Project with Pilot Flotation Program

Event summary

  • Defense Metals has commissioned SGS Canada to conduct a 30-tonne pilot-scale flotation test program on material from the Wicheeda Rare Earth Project.
  • The program, costing approximately CAD$1 million, will generate 1.5 tonnes of flotation concentrate for subsequent hydrometallurgical testing.
  • The testing aims to refine the process flowsheet and support the progression of the project from a pre-feasibility study to a feasibility stage.
  • The program utilizes drill core material representing Years 1-5 and Year 6+ of the proposed mining operation.
  • Defense Metals has granted 7.375 million incentive stock options to directors, officers, and consultants at a price of C$0.28 per share.

The big picture

The Wicheeda Project represents a key effort to establish a North American rare earth supply chain, reducing reliance on foreign sources and supporting strategic industries like defense and clean energy. This pilot program is a critical step in de-risking the project's metallurgical process, but the overall success hinges on achieving consistent, high-grade concentrate production and securing the necessary capital for continued development. The broader rare earth market is experiencing increased demand and geopolitical scrutiny, making projects like Wicheeda increasingly important.

What we're watching

Metallurgical Risk
The success of the hydrometallurgical pilot plant, dependent on the concentrate produced by SGS, will be crucial for validating the overall processing route and its economic viability.
Project Timeline
The pace of data generation and analysis from the pilot program will directly influence the timeline for advancing to the feasibility study and subsequent development stages.
Funding
Given the CAD$1 million cost of this program and the need for further studies (DFS), Defense Metals will need to secure additional funding to progress the Wicheeda Project to production.
Amplify Investments LLC

Amplify ETFs Launches Income-Targeted Covered Call ETFs

Event summary

  • Amplify ETFs filed for two new ETFs: the Amplify LQD Investment Grade 12% Target Income ETF (LQDM) and the Amplify HYG High Yield 10% Target Income ETF (HYGM).
  • The ETFs aim to generate target income (12% for LQDM, 10% for HYGM) through a covered call strategy on underlying bond ETFs.
  • LQDM tracks investment-grade corporate bonds, while HYGM focuses on high-yield bonds.
  • Amplify ETFs currently manages over $20 billion in assets under management as of January 31, 2026.
  • The new ETFs will be added to Amplify’s YieldSmart™ suite of income-focused ETFs.

The big picture

Amplify’s move signals continued investor demand for income-generating strategies, even within traditionally conservative asset classes like fixed income. The covered call approach attempts to enhance yield, but introduces complexities and potential limitations compared to traditional bond ETFs. The filing expands Amplify’s YieldSmart suite, reinforcing their focus on options-based income products within a broader ETF market increasingly saturated with specialized strategies.

What we're watching

Performance
The success of these ETFs will hinge on their ability to consistently achieve the stated 12% and 10% income targets, which will be heavily influenced by option pricing and underlying bond performance.
Investor Adoption
The pace of asset inflows into LQDM and HYGM will indicate investor appetite for this specific covered call strategy within the fixed income space, particularly given the inherent limitations of covered call strategies.
Competitive Landscape
How iShares and other fixed income ETF providers respond to Amplify’s offerings will shape the competitive dynamics within this niche segment of the ETF market.
NiCAN Limited

NiCAN Intersects High-Grade Nickel at Pipy South, Expanding Exploration Target

Event summary

  • NiCAN intersected 1.54% nickel, 0.17% copper, and 0.064% cobalt over 1.45 meters at a depth of 60 meters at the Pipy South Project in Manitoba.
  • The mineralization is located within the Pipe Formation, which hosts the Thompson Nickel Belt's economic nickel deposits, 20km north of Vale's Thompson Nickel Mine.
  • Geophysical surveys indicate the mineralized system is open to the north, south, up-dip, and down-dip, with a five-kilometer strike length.
  • Drilling also revealed a new gold zone on the property, prompting plans for dual nickel and gold exploration programs.

The big picture

NiCAN’s discovery at Pipy South represents a potentially significant addition to the Thompson Nickel Belt, a historically important mining region. The presence of both nickel and gold mineralization, coupled with existing infrastructure, could attract further investment and development. However, the geological complexity of the region, as highlighted by the polyphase deformation, suggests that exploration and resource definition will require sustained effort and technical expertise.

What we're watching

Exploration Pace
The speed at which NiCAN can delineate the extent of the newly discovered mineralization will be critical in assessing the project's overall value and potential for future development.
Geophysical Correlation
The correlation between geophysical anomalies and actual mineralization needs to be consistently validated through further drilling to refine exploration targets and reduce risk.
Gold Potential
The discovery of a new gold zone alongside the nickel mineralization could significantly broaden the project’s economic appeal, but its viability will depend on the size and grade of the deposit.
PSQ Holdings, Inc.

PSQ Holdings Posts Strong Revenue Growth, Cuts Losses Amid Strategic Overhaul

Event summary

  • PSQ Holdings reported preliminary Q4 2025 revenue of $7.3 million, up 109% year-over-year.
  • Full-year 2025 revenue reached $18.2 million, an 81% increase compared to 2024.
  • The company reduced operating expenses by 27% for the full year 2025, and net loss improved by 43% year-over-year.
  • PSQ Holdings has discontinued its Brands and Marketplace businesses, focusing on payments, consumer financing, and fundraising infrastructure.
  • As of December 31, 2025, the company held $15.8 million in cash and cash equivalents.

The big picture

PSQ Holdings' results reflect a broader trend of fintech companies streamlining operations and focusing on core competencies to achieve profitability. The shift to discontinue non-core businesses and the emphasis on AI-driven efficiency suggest a recognition of the need to adapt to a more competitive and challenging market environment. The company's ability to execute on its strategic plan and rebuild investor trust will be key to its long-term success.

What we're watching

Unit Economics
Whether the cost reduction initiatives and focus on core businesses will translate into sustainable improvements in unit economics remains to be seen, particularly as the company scales its payments infrastructure.
Cash Burn
The company's stated goal of reducing cash burn will be critical to long-term viability; monitoring cash flow and capital allocation decisions will be essential.
AI Integration
The effectiveness of AI deployment as a 'force multiplier' will determine if PSQ Holdings can maintain its operational momentum and achieve its stated efficiency goals.
Skeena Resources Limited

Skeena Updates Eskay Creek Construction, Eyes Q2 2027 Production

Event summary

  • Skeena Gold & Silver released a video update on February 17, 2026, showcasing construction progress at its Eskay Creek gold-silver project.
  • The video features Skeena's Executive Chairman Walter Coles, CEO Randy Reichert, VP of Operations Kyle Foster, and VP of Project Engineering & Construction Andrew Osterloh.
  • Eskay Creek is expected to achieve initial production and cash flow in Q2 2027.
  • The project is described as one of the world’s highest-grade and lowest-cost open-pit precious metals mines, with significant silver byproduct production.

The big picture

Skeena's Eskay Creek project represents a significant bet on high-grade precious metals production in a region known for its geological potential. The company's focus on efficiency and low costs is crucial given the current inflationary environment and increasing operational expenses within the mining sector. Successful execution of this project could establish Skeena as a key player in the global silver market, but also carries substantial risk given the capital intensity and operational complexity of mining ventures.

What we're watching

Execution Risk
The video's emphasis on schedule adherence highlights the inherent risks in large-scale mining projects, and any deviations from the stated timeline will be closely scrutinized by investors.
Commodity Prices
The project's profitability is heavily reliant on gold and silver prices, and a significant downturn in either metal could impact the project's economics and Skeena's shareholder returns.
Permitting
While the project is currently permitted, ongoing environmental and regulatory scrutiny could introduce delays or increased costs, impacting the projected timeline and budget.
Brown & Brown, Inc.

Brown & Brown Bolsters Dealer Services with American Adventure Acquisition

Event summary

  • Brown & Brown’s Dealer Services division (BBDS) acquired the assets of American Adventure Insurance.
  • American Adventure specializes in insurance solutions for dealerships, including motor homes, travel trailers, and F&I products.
  • Paul Bender, owner of American Adventure, will continue to lead the team and report to Mike Neal, president of BBDS.
  • American Adventure serves over 1,500 dealerships nationwide.

The big picture

Brown & Brown’s acquisition of American Adventure signals a continued strategic focus on expanding its dealer services offerings, a niche market with specialized needs. The deal, while not disclosed in terms of value, demonstrates the firm’s willingness to acquire specialized agencies to broaden its product portfolio and geographic reach. This move aligns with the broader trend of insurance brokerages seeking to deepen relationships with specific industry verticals to gain a competitive advantage.

What we're watching

Integration Risk
The success of the acquisition hinges on BBDS’s ability to integrate American Adventure’s dealer-centric model without disrupting existing operations or losing key personnel.
Dealer Dependence
BBDS’s reliance on a network of dealerships for revenue exposes it to cyclical downturns in the automotive and recreational vehicle markets.
Competitive Landscape
The acquisition may intensify competition within the dealer services insurance space, potentially leading to pricing pressures and margin erosion.
Compass Pathfinder Limited

Compass Pathways' COMP360 Phase 3 Data Bolsters Regulatory Path for TRD Treatment

Event summary

  • Compass Pathways announced positive top-line results for its Phase 3 COMP006 trial evaluating COMP360 (psilocybin) for treatment-resistant depression (TRD).
  • The trial’s primary endpoint, change in MADRS scores at Week 6, showed a statistically significant reduction (-3.8 points, p<0.001) with a 25mg dose compared to a 1mg control.
  • Combined data from COMP005 and COMP006 suggest durable treatment effects lasting at least 26 weeks with a single or two doses of 25mg COMP360.
  • Compass plans to submit a rolling NDA to the FDA in Q4 2026, following a meeting to discuss the submission process.

The big picture

Compass Pathways’ consistent Phase 3 results represent a significant advancement in the treatment of TRD, a market with limited therapeutic options and a substantial unmet need. The company’s focus on psilocybin-based therapies positions it at the forefront of a nascent wave of psychedelic-assisted treatments, but regulatory and reimbursement hurdles remain substantial. Success hinges on demonstrating a compelling value proposition to both clinicians and payers.

What we're watching

Regulatory Risk
The FDA’s receptiveness to Compass’s proposed rolling NDA submission and potential for accelerated approval will be a key determinant of commercial launch timelines.
Durability Data
The 26-week data from COMP006, expected in early Q3 2026, will be critical in validating the long-term efficacy and potential for reduced retreatment frequency.
Market Adoption
The willingness of payers to reimburse COMP360, given its novel mechanism of action and potential for high cost, will significantly impact market penetration within the TRD patient population.
VIAVI Solutions

VIAVI Unveils Cesium-Free Timing Tech, Challenging Critical Infrastructure Standards

Event summary

  • VIAVI Solutions launched the ePRTC360+ holdover solution, a Cesium-free alternative for precise timing.
  • The ePRTC360+ meets the ITU-T G.8272.1 drift standard, previously achievable only with Cesium clocks.
  • VIAVI claims the ePRTC360+ offers significantly lower cost than Cesium clocks, enabling wider deployment.
  • The technology utilizes a resilient altGNSS GEO-L service and integrated anti-jamming/spoofing antennas.
  • VIAVI will demonstrate the ePRTC360+ at Mobile World Congress in Barcelona, March 2026.

The big picture

The launch of the ePRTC360+ reflects a growing concern over GNSS vulnerabilities and the need for resilient timing solutions across critical infrastructure. The reliance on GNSS for timing is increasingly recognized as a single point of failure, particularly as 5G networks and AI data centers demand ever-more precise synchronization. VIAVI's offering addresses a significant market need by providing a cost-effective alternative to expensive and logistically challenging Cesium clocks, potentially opening up new deployment opportunities at scale.

What we're watching

Adoption Rate
The speed at which operators adopt the ePRTC360+ will depend on their existing infrastructure and the perceived risk of GNSS disruptions, potentially displacing legacy Cesium clock deployments.
GEO-L Dependence
VIAVI's reliance on the GEO-L service introduces a new point of failure; the availability and resilience of this service will be crucial to the ePRTC360+'s overall reliability.
Standard Evolution
Future revisions to the ITU-T G.8272.1 standard could tighten requirements, potentially requiring VIAVI to further innovate or risk obsolescence.
Project Mumbai

COP30 Presidency Prioritizes Implementation at Mumbai Climate Week

Event summary

  • The COP30 Presidency is emphasizing implementation over negotiation at Mumbai Climate Week (February 17-19, 2026).
  • COP31, hosted by Türkiye, will take place November 9-20, 2026, and is being coordinated with the COP30 Presidency.
  • A 'Global Implementation Accelerator' (GIA) was adopted at COP30, prioritizing methane reduction and nature-based carbon removal.
  • The 'Action Agenda' has been restructured around six thematic areas derived from the first Global Stocktake (GST).

The big picture

The COP Presidencies are attempting to shift the focus of climate action away from protracted negotiations and toward concrete implementation, recognizing the urgency of the climate crisis. This move reflects a broader trend toward decentralized, action-oriented approaches within the climate governance landscape. The emphasis on the GIA and the GST suggests a recognition that achieving Paris Agreement goals requires a more targeted and results-driven strategy.

What we're watching

Implementation Risk
The success of the GIA hinges on translating prioritized actions into tangible results, which may be hampered by bureaucratic inertia and conflicting national interests.
Coordination Challenges
Maintaining alignment between the COP30 and COP31 Presidencies, along with the High-Level Climate Champions, will be crucial for ensuring continuity and avoiding policy fragmentation.
GST Embedding
The extent to which Climate Weeks and other forums genuinely integrate the six GST thematic areas will determine the effectiveness of the COP30’s strategic shift.
IDEAYA Biosciences, Inc.

IDEAYA Biosciences Pipeline Advances as Cash Reserves Extend Runway

Event summary

  • IDEAYA Biosciences ended 2025 with ~$1.05 billion in cash, cash equivalents, and marketable securities, projecting funding into 2030.
  • Enrollment is complete for the Phase 2/3 OptimUM-02 trial in HLA*A2-negative metastatic uveal melanoma, with topline results expected by late March 2026.
  • The company plans to initiate a registrational study for IDE849 (DLL3 TOP1 ADC) in 2L+ small cell lung cancer/neuroendocrine carcinoma by year-end 2026.
  • GSK terminated its collaboration agreement with IDEAYA, transferring the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA.

The big picture

IDEAYA’s progress highlights the increasing focus on precision medicine in oncology, with targeted therapies like darovasertib and ADCs like IDE849 representing a shift towards more personalized treatment approaches. The termination of the GSK collaboration, while resulting in the return of assets, underscores the ongoing restructuring within the pharmaceutical industry as companies reassess their portfolios and strategic partnerships. With a significant cash position, IDEAYA is well-positioned to pursue its pipeline ambitions, but execution risk remains a key factor in its long-term success.

What we're watching

Clinical Execution
The topline PFS data from the OptimUM-02 trial will be critical in determining the potential for accelerated approval and the overall viability of darovasertib as a treatment for uveal melanoma.
Pipeline Diversification
IDEAYA’s ability to advance its ADC and MTAP pathway programs, particularly IDE849 and IDE397, will be key to mitigating risk and expanding its therapeutic reach beyond uveal melanoma.
Financial Discipline
The substantial cash reserves will be tested as IDEAYA moves into Phase 3 trials and initiates new programs; management's ability to maintain a long cash runway will be essential for continued operation.
Allegion plc

Allegion's Organic Growth Slows Amidst Price Realization

Event summary

  • Allegion reported Q4 2025 net revenues of $1.03 billion, up 9.3% year-over-year.
  • Organic revenue growth slowed to 3.3% in Q4 2025, driven by price realization offsetting volume declines.
  • The Americas non-residential business saw high-single-digit organic growth, while the residential business declined high-single digits.
  • Allegion expects full-year 2026 revenues to increase 5% to 7% reported, and 2% to 4% organically.
  • The company projects full-year 2026 adjusted EPS between $8.00 and $8.20.

The big picture

Allegion's results highlight a mixed picture for the security products sector. While the company demonstrates pricing power, slowing organic growth in key segments suggests a potential softening in demand. The company's reliance on acquisitions to drive revenue growth introduces integration risk and could impact long-term profitability. The $4.1 billion revenue company's ability to navigate these challenges will be critical for sustaining shareholder value.

What we're watching

Residential Demand
The continued weakness in the residential segment warrants close monitoring, as it could signal broader shifts in housing market activity and consumer spending.
Pricing Pressure
Whether Allegion can maintain price realization in 2026 will be crucial, as cost pressures and competitive dynamics could erode margins.
Acquisition Integration
The success of Allegion’s acquisition strategy in driving organic growth and margin expansion will be key to meeting its 2026 outlook.
Milliman, Inc.

Multiemployer Pension Funding Surges to Historic High Amid Asset Gains

Event summary

  • Milliman's 2025 Multiemployer Pension Funding Study (MPFS) reveals an aggregate funded percentage of 103% as of December 31, 2025.
  • This marks the highest funded percentage in the 20-year history of the MPFS, a 50-percentage-point improvement since the 2008 financial crisis.
  • Strong asset gains, contributing to a 13.9% portfolio return in 2025, were a primary driver of the funding increase.
  • Total contributions to multiemployer plans have exceeded benefit expenses and administrative costs, totaling $331 billion versus $212 billion over the past decade.
  • Approximately $75 billion of the $79 billion allocated through the American Rescue Plan Act’s Special Financial Assistance (SFA) program has been distributed.

The big picture

The significant improvement in multiemployer pension funding represents a notable turnaround from the challenges faced during and after the 2008 financial crisis. While asset gains have played a substantial role, proactive measures like increased contributions and benefit adjustments have also contributed. However, the reliance on market performance and the temporary nature of SFA funding highlight ongoing vulnerabilities within the system.

What we're watching

Asset Volatility
The reliance on strong asset performance to bolster funding levels leaves multiemployer plans vulnerable to market downturns, potentially reversing recent gains.
Contribution Sustainability
The continued ability of plans to maintain or increase contribution rates will be crucial for sustaining the current funded status, given demographic pressures and potential economic headwinds.
SFA Impact
The remaining $4 billion of SFA funds will be distributed, but the long-term impact of this temporary boost on plan solvency remains to be seen.
Teva Pharmaceutical Industries Ltd.

Teva's Duvakitug Data Bolsters IBD Pipeline, Long-Term Efficacy Confirmed

Event summary

  • Phase 2b data from the RELIEVE UCCD LTE study demonstrated durable efficacy of duvakitug (anti-TL1A) for up to 44 weeks in patients with ulcerative colitis (UC) and Crohn’s disease (CD) who had previously responded.
  • Efficacy rates at week 44 were 58% (900mg) and 47% (450mg) for UC, and 55% (900mg) and 41% (450mg) for CD, achieving primary endpoints.
  • The study enrolled 130 patients and utilized a randomized, double-blinded design with doses of 450mg and 900mg administered subcutaneously every four weeks.
  • Teva and Sanofi are co-developing and co-commercializing duvakitug, sharing development costs and profits/losses.

The big picture

The IBD market remains a significant unmet need, with current treatments often failing to provide sustained remission. Duvakitug's durable efficacy data represents a potential advancement, but the crowded competitive landscape and the inherent risks of drug development mean success is far from guaranteed. Teva's pivot to innovative biopharmaceuticals hinges on the success of this collaboration with Sanofi, and the long-term commercial viability of duvakitug.

What we're watching

Phase 3 Progress
The success of these Phase 2b data will heavily influence the trajectory of duvakitug's Phase 3 trials; any setbacks could significantly impact Teva's pipeline and valuation.
Commercialization Strategy
The geographic split of commercialization responsibilities between Teva and Sanofi will be critical; differing regulatory landscapes and market access challenges could create friction or missed opportunities.
TL1A Validation
Further clinical data and competitor activity will determine whether TL1A remains a validated target for IBD treatment, or if other approaches prove more effective.
ARCTIC WOLF NETWORKS, INC.

Data Extortion Surges 11x, Forcing Cybersecurity Shift

Event summary

  • Arctic Wolf's 2026 Threat Report reveals a dramatic 11x increase in data extortion incidents year-over-year.
  • Ransomware, BEC, and data incidents collectively accounted for 92% of Arctic Wolf's incident response engagements.
  • 65% of non-BEC intrusions exploited remote access tools (RDP, VPN, RMM), a significant increase.
  • Organizations that invested in visibility, identity security, and disciplined remote access controls demonstrated greater resilience.
  • Phishing attacks, driving 85% of BEC incidents, are becoming more convincing due to AI advancements.

The big picture

The Arctic Wolf report highlights a significant evolution in cybercriminal tactics, moving away from traditional ransomware encryption towards data theft and extortion. This shift is likely a response to improved organizational recovery capabilities and underscores the growing importance of data security as a core business risk. The prevalence of remote access tool abuse points to a broader trend of attackers exploiting readily available vulnerabilities rather than pursuing complex exploits, demanding a renewed focus on basic security hygiene across organizations.

What we're watching

Attack Vector Evolution
The continued reliance on easily exploitable remote access tools suggests attackers will prioritize low-hanging fruit over complex vulnerability exploitation, requiring organizations to harden these access points aggressively.
Data Security Focus
The shift towards data extortion, rather than encryption, indicates that organizations' ability to recover from ransomware attacks has improved, forcing attackers to prioritize data theft for leverage.
AI-Driven Threats
The increasing sophistication of phishing attacks, fueled by AI, will likely necessitate continuous investment in employee training and advanced email security measures to mitigate BEC risks.
Sum and Substance Ltd.

Sumsub Launches AI Copilot Amid Rising Fraud, Regulatory Pressure

Event summary

  • Sumsub launched 'Summy,' an AI Copilot integrated into its verification and fraud prevention platform.
  • Summy evolved from an AI Assistant focused on case management to a platform-wide AI agent.
  • AI-powered fraud schemes increased 180% year-over-year globally in 2025, according to Sumsub's report.
  • Summy aims to improve productivity for compliance teams by up to three times, on average.
  • Svetlana Shchennikova, KYC Product Ops Lead at Mercuryo, highlighted Summy’s value in streamlining workflows.

The big picture

Sumsub's launch of Summy reflects a broader trend of AI adoption within compliance and fraud prevention, driven by the escalating sophistication of fraud attacks and increasing regulatory scrutiny. The 180% surge in AI-powered fraud schemes underscores the urgent need for advanced tools, while regulations like the EU AI Act are forcing companies to prioritize transparency and explainability in their AI deployments. Summy's design, emphasizing human control and auditability, positions Sumsub to navigate this complex landscape.

What we're watching

Regulatory Headwinds
The effectiveness of Summy's compliance advice feature will be tested as regulators like the EU and Singapore continue to tighten AI-related rules, demanding greater transparency and accountability.
Execution Risk
Sumsub's ability to maintain the claimed 3x productivity gains across diverse client workflows and regulatory environments will be a key indicator of Summy's long-term value proposition.
Governance Dynamics
The market will scrutinize how Sumsub balances AI-driven automation with human oversight to ensure decisions remain traceable and aligned with established compliance policies, avoiding accusations of 'black-box' decision-making.